Skip to main content Skip to main content
Go to homepage

Study to determine the safety/tolerability of SNDX-5613

Study to determine the safety and tolerability of SNDX-5613 in patients with relapsed/refractory leukemia


For complete information, please visit the study at

Interested in participating?
We are currently recruiting
Study Sponsor:

Syndax Pharmaceuticals; Children's Oncology Group

Full IRB Study Title:
AALL2121-A Phase 2 study of SNDX-5613 in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia
IRB Study ID:
If you are interested in this study or have questions about your child's eligibility, please contact:

Kelly Culp: 330-543-0108

Lead Investigator
Erin Wright, MD

Director, Neuro-Oncology; Director, Shannon E. Wilkes Targeted Therapy Program; Co-Director, Neurofibromatosis Clinic; Pediatric Neuro-Oncologist
Pediatric Brain Tumor ProgramShowers Family Center for Childhood Cancer and Blood DisordersNeurofibromatosis (NF) Clinic

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.